-
公开(公告)号：US20220062550A1
公开(公告)日：2022-03-03
申请号：US17412684
申请日：2021-08-26
Applicant: Insulet Corporation
Inventor： David NAZZARO , Jason O'CONNOR , Ian MCLAUGHLIN , Joon Bok LEE , Thomas METZMAKER , Bret CHRISTENSEN , Philip HILLDALE
Abstract: Embodiments of the present disclosure relate to approaches for transitioning a drug delivery device from a low-energy sleep state to a high-energy active state. In some embodiments, a system may include a drug delivery device, the drug delivery device including a pump mechanism coupled to a reservoir for expelling a liquid drug from the reservoir; and an activation component communicatively coupled to the pump mechanism. The activation component may include at least one of a sensor and a mechanical activation device, and a wake-up circuit operable to receive an input from the sensor or the mechanical activation device, wherein the input indicates a change in a device characteristic. Based on the change in the device characteristic, the wake-up circuit may be further operable to transition the drug delivery device from a low-energy state to an active state.
-
公开(公告)号：US20220031944A1
公开(公告)日：2022-02-03
申请号：US16945246
申请日：2020-07-31
Applicant: Insulet Corporation
Inventor： Yibin ZHENG , Joon Bok LEE , Jason O'CONNOR
Abstract: Disclosed are techniques to establish a modified pump rate that mitigates the effects of a pump occlusion and enables a recommended dosage of insulin to be output by a pump mechanism over the course of a control cycle. In an example, the pump rate may be reduced by adding a calculated time interval between application of actuation commands to extend the amount of time over which insulin may be output by the pump mechanism.
-
公开(公告)号：US20210308377A1
公开(公告)日：2021-10-07
申请号：US16840483
申请日：2020-04-06
Applicant: INSULET CORPORATION
Inventor： Mengdi LI , Joon Bok LEE , Jason O'CONNOR , Yibin ZHENG
IPC: A61M5/172 , G16H40/67 , G16H10/60 , G16H20/17 , G16H50/20 , G16H50/70 , G16H10/40 , G16H50/30 , G16H50/50
Abstract: Disclosed are techniques to establish initial settings for an automatic insulin delivery device. An adjusted total daily insulin (TDI) factor usable to calculate a TDI dosage may be determined. The adjusted TDI factor may be a TDI per unit of a physical characteristic of the user (e.g., weight) times a reduction factor. The adjusted TDI factor may be compared to a maximum algorithm delivery threshold. Based on the comparison result, the application or algorithm may set a TDI dosage and output a control signal. Blood glucose measurement values may be collected from a sensor over a period of time. A level of glycated hemoglobin of the blood may be determined based on the obtained blood glucose measurement values. In response to the level of glycated hemoglobin, the set TDI dosage may be modified. A subsequent control signal including the modified TDI dosage may be output to actuate delivery of insulin.
-
公开(公告)号：US20210236730A1
公开(公告)日：2021-08-05
申请号：US17166072
申请日：2021-02-03
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Ashutosh ZADE , Jason O'CONNOR , Yibin ZHENG , Steven CARDINALI
Abstract: In an automated insulin delivery device, fuzzy logic may be applied to the responding to the possibility of a user taking additional action that may affect the blood glucose concentration. Fuzzy sets may be defined for empirically derived different likelihoods of the user taking such additional action based on correlated factors. A membership function may be provided for each fuzzy set. The membership function may provide a probability of membership in the set based on a parameter. Each fuzzy set may have a response that is reflective of the likelihood of additional user action associated with the fuzzy set. The responses by the AID device to each of these cases may reflect the probability of each such case occurring as evidenced by empirical data.
-
公开(公告)号：US20210187197A1
公开(公告)日：2021-06-24
申请号：US17123378
申请日：2020-12-16
Applicant: Insulet Corporation
Inventor： Ashutosh ZADE , Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR
Abstract: Disclosed are devices, a system, methods and computer-readable medium products that provide techniques to implement functionality to determine when to softened upper bounds of drug delivery and how much to soften the upper bound. Future blood glucose measurement values may be predicted by calculating deviations between predicted blood glucose measurement values and additional blood glucose measurement values. A gain parameter may be determined for use with a model of predicting a user's blood glucose measurement values and determining future drug dosages. Safety constraints may be determined based on an evaluation of missing blood glucose measurement values. In addition, safety constraints may be determined based on an evaluation of a user's increased interaction with an automatic drug delivery device. A bolus uncertainty metric to determine an amount of insulin to be provided in a bolus dosage in response to a bolus request may be calculated.
-
Patent Agency Ranking
公开(公告)号：US20210170104A1
公开(公告)日：2021-06-10
申请号：US17112314
申请日：2020-12-04
Applicant: INSULET CORPORATION
Inventor： Yibin ZHENG , Joon Bok LEE , Steven CARDINALI , Jason O'CONNOR , Eric BENJAMIN , Ian MCLAUGHLIN , David NAZZARO , Ashutosh ZADE
IPC: A61M5/172 , A61M5/142 , G16H40/67 , G16H20/17 , G16H50/70 , G16H10/60 , G16H50/30 , G16H40/40 , G16H20/60 , G01N33/49
Abstract: Disclosed are a device, system, methods and computer-readable medium products that provide an updated insulin-to-carbohydrate ratio and an updated total daily insulin. The described processes may be used for periodic updating of the insulin-to-carbohydrate ratio and the total daily insulin. The insulin-to-carbohydrate ratio and/or the total may be used in the calculation of new doses of insulin that a drug delivery device may be commanded to deliver to a user.
-
公开(公告)号：US20250132007A1
公开(公告)日：2025-04-24
申请号：US18909496
申请日：2024-10-08
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Ashutosh ZADE , Yibin ZHENG , Jason O’CONNOR
Abstract: A medicament delivery system, process and techniques are provided. The medicament delivery system may include a wearable medicament delivery device, a memory storing programming instructions, and a processor. The processor may be operable to execute the programming instructions, which cause the processor to receive an available medicament delivery history of a user, and determine whether the available medicament delivery history spans an extent of time greater than a first glucose history duration. The processor, in response to a determination that the extent of time spanned by the available medicament delivery history is greater than the first glucose history duration, determines an average daily medicament delivered. The processor calculates a trust value of the available medicament delivery history, and utilizes the trust value to determine a total daily medicament value of the user.
-
公开(公告)号：US20250050021A1
公开(公告)日：2025-02-13
申请号：US18797048
申请日：2024-08-07
Applicant: INSULET CORPORATION
Inventor： Yibin ZHENG , Joon Bok LEE , William WHITELEY , Jason O’CONNOR
Abstract: Exemplary embodiments may configure the glucose cost component of a cost function used in determining basal insulin delivery doses to be limited by the maximum physiological rate of glucose level change over a time period so that the cost function more accurately reflects the physical limits of change due to insulin action, As a result, the glucose cost component of the cost function may more accurately reflect the response of a user to basal insulin deliveries, resulting in better insulin control for the user. Exemplary embodiments may modify the aggressiveness of a control approach based on a current target glucose level versus a nominal target glucose level for which the control approach was designed.
-
公开(公告)号：US20240399059A1
公开(公告)日：2024-12-05
申请号：US18804372
申请日：2024-08-14
Applicant: INSULET CORPORATION
Inventor： Jason O'CONNOR , Joon Bok LEE , Trang LY , Yibin ZHENG , Thomas Arnold PEYSER , Jennifer Lena SCHNEIDER
Abstract: Disclosed are a system, methods and computer-readable medium products that provide safety constraints for an insulin-delivery management program. Various examples provide safety constraints for a control algorithm-based drug delivery system that provides automatic delivery of a drug based on sensor input. Glucose measurement values may be received at regular time intervals from a sensor. A processor may predict future glucose values based on prior glucose measurement values. The safety constraints assist in safe operation of the drug delivery system during various operational scenarios. In some examples, predicted future glucose values may be used to implement safety constraints that mitigate under-delivery or over-delivery of the drug while not overly burdening the user of the drug delivery system and without sacrificing performance of the drug delivery system. Other safety constraints are also disclosed.
-
90.发明公开公开(公告)号：US20240325640A1
公开(公告)日：2024-10-03
申请号：US18618579
申请日：2024-03-27
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , John D’ARCO , Yibin ZHENG , Jason O’CONNOR
CPC classification number: A61M5/1723 , G16H20/17
Abstract: A drug delivery system including a memory storing programming code operable to control delivery of a drug, a user interface operable to accept an input indicating a perceived glucose state of a user, and a processor operable to execute the programming code. When executed, the programming code causes the processor to: receive a perceived state signal from the user interface indicating the perceived glucose state of the user, evaluate the perceived glucose state of the user indicated by the perceived state signal using a glucose measurement value corresponding in time to when the perceived state signal was received, determine an adjustment to a drug delivery algorithm, and utilize the adjustment in a determination of a drug delivery dosage to be administered to a user.
-
-
-
-
-
-
-
-
-
Search Results
111
records
(took 0.017 seconds)
